News | November 07, 2025
Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
The device delivers clear, high-quality images to support accurate diagnoses across a broad range of patient groups
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
Subscribe To Our Newsletter & Stay Updated
